The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Open accessAbstract
Purpose: Nilotinib is a second-generation tyrosine kinase inhibitor indicated for the treatment of patients with chronic myeloid leukemia (CML) in chronic phase (CP; CML-CP) and accelerated phase (AP; CML-AP) who are resistant to or intolerant of prior imatinib therapy. In this subanalysis of a phase II study of nilotinib in patients with imatinib-resistant or imatinib-intolerant CML-CP, the occurrence and impact of baseline and newly detectable BCR-ABL mutations were assessed. Patients and Methods: Baseline mutation data were assessed in 281 (88%) of 321 patients with CML-CP in the phase II nilotinib registration trial. Results: Among imatinib-resistant patients, the frequency of mutations at baseline was 55%. After 12 months of therapy, major cytogenetic response (MCyR) was achieved in 60%, complete cytogenetic response (CCyR) in 40%, and major molecular response (MMR) in 29% of patients without baseline mutations versus 49% (P = .145), 32% (P = .285), and 22% (P = .366), respectively, of patients with mutations. Responses in patients who harbored mutations with high in vitro sensitivity to nilotinib (50% inhibitory concentration [IC 50 ] ≤ 150 nM) or mutations with unknown nilotinib sensitivity were equivalent to those responses for patients without mutations (not significant). Patients with mutations that were less sensitive to nilotinib in vitro (IC 50 > 150 nM; Y253H, E255V/K, F359V/C) had less favorable responses, as 13%, 43%, and 9% of patients with each of these mutations, respectively, achieved MCyR; none achieved CCyR. Conclusion: For most patients with imatinib resistance and with mutations, nilotinib offers a substantial probability of response. However, mutational status at baseline may influence response. Less sensitive mutations that occurred at three residues defined in this study, as well as the T315I mutation, may be associated with less favorable responses to nilotinib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationShah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Hughes, T. (2006) · Blood · doi:10.1182/blood-2006-01-0092 · Cited by 1,199
Self-citationMolecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Self-citationBranford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., Taylor, K., Herrmann, R., Seymour, J. F., Arthur, C., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2896 · Cited by 765
Self-citationKantarjian, H. M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Ossenkoppele, G. J., Nicolini, F.-E., O'Brien, S. G., Litzow, M., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080689 · Cited by 746
Self-citationBranford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K. P., & Hughes, T. P. (2002) · Blood · doi:10.1182/blood.v99.9.3472 · Cited by 649
Self-citationSoverini, S., Colarossi, S., Gnani, A., Rosti, G., Castagnetti, F., Poerio, A., Iacobucci, I., Amabile, M., Abruzzese, E., Orlandi, E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1516 · Cited by 511
Self-citationAMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
Weisberg, E., Manley, P., Mestan, J., Cowan-Jacob, S., Ray, A., & Griffin, J. D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603170 · Cited by 484
Shah, N. P., Skaggs, B. J., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30890 · Cited by 418
Self-citationSoverini, S., Martinelli, G., Rosti, G., Bassi, S., Amabile, M., Poerio, A., Giannini, B., Trabacchi, E., Castagnetti, F., Testoni, N., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.531 · Cited by 374
Self-citationImatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance
Hochhaus, A., & La Rosée, P. (2004) · Leukemia · doi:10.1038/sj.leu.2403426 · Cited by 336
Self-citationWillis, S. G., Lange, T., Demehri, S., Otto, S., Crossman, L., Niederwieser, D., Stoffregen, E. P., McWeeney, S., Kovacs, I., Park, B., et al. (2005) · Blood · doi:10.1182/blood-2005-03-1036 · Cited by 302
le Coutre, P., Ottmann, O. G., Giles, F., Kim, D.-W., Cortes, J., Gattermann, N., Apperley, J. F., Larson, R. A., Abruzzese, E., O'Brien, S. G., et al. (2008) · Blood · doi:10.1182/blood-2007-04-083196 · Cited by 294
Self-citationCorbin, A. S., Rosée, P. L., Stoffregen, E. P., Druker, B. J., & Deininger, M. W. (2003) · Blood · doi:10.1182/blood-2002-12-3659 · Cited by 258
Lahaye, T., Riehm, B., Berger, U., Paschka, P., Müller, M. C., Kreil, S., Merx, K., Schwindel, U., Schoch, C., Hehlmann, R., et al. (2005) · Cancer · doi:10.1002/cncr.20922 · Cited by 232
Self-citationEvidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
Mahon, F.-X., Hayette, S., Lagarde, V., Belloc, F., Turcq, B., Nicolini, F., Belanger, C., Manley, P. W., Leroy, C., Etienne, G., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1008 · Cited by 212
Golemovic, M., Verstovsek, S., Giles, F., Cortes, J., Manshouri, T., Manley, P. W., Mestan, J., Dugan, M., Alland, L., Griffin, J. D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2601 · Cited by 203
Self-citationBranford, S., Cross, N. C. P., Hochhaus, A., Radich, J., Saglio, G., Kaeda, J., Goldman, J., & Hughes, T. (2006) · Leukemia · doi:10.1038/sj.leu.2404388 · Cited by 196
Self-citationSoverini, S., Colarossi, S., Gnani, A., Castagnetti, F., Rosti, G., Bosi, C., Paolini, S., Rondoni, M., Piccaluga, P. P., Palandri, F., et al. (2007) · Haematologica · doi:10.3324/haematol.10822 · Cited by 189
Self-citationDeininger, M. W., Cortes, J. E., Paquette, R. L., Park, B. S., Hochhaus, A., Baccarani, M., Stone, R. M., Fischer, T., Kantarjian, H. M., Niederwieser, D. W., et al. (2007) · Cancer · doi:10.1002/cncr.22936 · Cited by 132
Self-citationRay, A., Cowan‐Jacob, S. W., Manley, P. W., Mestan, J., & Griffin, J. D. (2007) · Blood · doi:10.1182/blood-2006-01-015347 · Cited by 128
Part II: Management of resistance to imatinib in chronic myeloid leukaemia
Apperley, J. F. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70379-0 · Cited by 111
Sherbenou, D. W., Wong, M. J., Humayun, A., McGreevey, L. S., Harrell, P. M., Yang, R., Mauro, M. J., Heinrich, M. C., Press, R. D., Druker, B. J., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404554 · Cited by 79
Ernst, T., Hoffmann, J., Erben, P., Hanfstein, B., Leitner, A., Hehlmann, R., Hochhaus, A., & Muller, M. C. (2008) · Haematologica · doi:10.3324/haematol.12964 · Cited by 50
Self-citationSoverini, S., Martinelli, G., Colarossi, S., Gnani, A., Rondoni, M., Castagnetti, F., Paolini, S., Rosti, G., & Baccarani, M. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70078-5 · Cited by 42
Self-citation
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Soverini, S., Hochhaus, A., Nicolini, F. E., Gruber, F., Lange, T., Saglio, G., Pane, F., Müller, M. C., Ernst, T., Rosti, G., et al. (2011) · Blood · doi:10.1182/blood-2010-12-326405 · Cited by 589
Self-citationChronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
Jabbour, E., & Kantarjian, H. (2018) · American Journal of Hematology · doi:10.1002/ajh.25011 · Cited by 413
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
Jabbour, E., & Kantarjian, H. (2020) · American Journal of Hematology · doi:10.1002/ajh.25792 · Cited by 410
Apperley, J. F. (2015) · The Lancet · doi:10.1016/s0140-6736(13)62120-0 · Cited by 381
Metadata
- Authors
- Hughes, T., Saglio, G., Branford, S., Soverini, S., Kim, D.-W., Müller, M. C., Martinelli, G., Cortes, J., Beppu, L., Gottardi, E., Kim, D., Erben, P., Shou, Y., Haque, A., Gallagher, N., Radich, J., & Hochhaus, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-09-01
- Volume
- 27
- Issue
- 25
- Pages
- 4204-4210
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1995670055
- Cited by
- 306
- References
- 27
- FWCI
- 25.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.